Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 22: 1697-1701, 1976;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bailey, D.
Right arrow Articles by Jatlow, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bailey, D.
Right arrow Articles by Jatlow, P.

Clinical Chemistry, Vol 22, 1697-1701, Copyright © 1976 by American Association for Clinical Chemistry

Gas-chromatographic analysis for therapeutic concentration of imipramine and disipramine in plasma, with use of a nitrogen detector

DN Bailey and PI Jatlow

We describe a method for the simultaneous gas-chromatographic analysis of imipramine and desipramine (the active N-desmethyl metabolite) at therapeutic concentrations in human plasma, with use of a nitrogen detector. Imipramine is measured as the unchanged base and desipramine as its N-tribluoroacetyl derivative. Promazine is the internal standard. The lower limit of sensitivity is 5 mug/liter for each drug, and the within-day coefficients of variation for the determination of imipramine and desipramine, respectively, are 6.0% and 3.3%. We measured concentrations of these drugs both in patients receiving therapeutic doses of imipramine and in those who had ingested an overdose.


The following articles in journals at HighWire Press have cited this article:


Home page
 Hum Exp ToxicolHome page
W.P. Tormey, H. Crosse, and A. Pierce
Chemical Toxicology for the Coroner
Human and Experimental Toxicology, September 1, 1989; 8(5): 375 - 379.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. Puig-Antich, J. M. Perel, W. Lupatkin, W. J. Chambers, M. A. Tabrizi, J. King, R. Goetz, M. Davies, and R. L. Stiller
Imipramine in Prepubertal Major Depressive Disorders
Arch Gen Psychiatry, January 1, 1987; 44(1): 81 - 89.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. C. Nelson, C. Mazure, D. M. Quinlan, and P. I. Jatlow
Drug-Responsive Symptoms in Melancholia
Arch Gen Psychiatry, July 1, 1984; 41(7): 663 - 668.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. C. Nelson, P. I. Jatlow, and D. M. Quinlan
Subjective Complaints During Desipramine Treatment: Relative Importance of Plasma Drug Concentrations and the Severity of Depression
Arch Gen Psychiatry, January 1, 1984; 41(1): 55 - 59.
[Abstract] [PDF]

Home page
 Hum Exp ToxicolHome page
A.H. Stead and A.C. Moffat
A Collection of Therapeutic, Toxic and Fatal Blood Drug Concentrations in Man
Human and Experimental Toxicology, January 1, 1983; 2(3): 437 - 464.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. C. Nelson, P. Jatlow, D. M. Quinlan, and M. B. Bowers Jr
Desipramine Plasma Concentration and Antidepressant Response
Arch Gen Psychiatry, December 1, 1982; 39(12): 1419 - 1422.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. C. Nelson, P. I. Jatlow, J. Bock, D. M. Quinlan, and M. B. Bowers Jr
Major Adverse Reactions During Desipramine Treatment: Relationship to Plasma Drug Concentrations, Concomitant Antipsychotic Treatment, and Patient Characteristics
Arch Gen Psychiatry, September 1, 1982; 39(9): 1055 - 1061.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by the American Association for Clinical Chemistry.